Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
top of page
HEALTH
&
BIOTECHNOLOGY
Financial Post: Skylight Health Group
From an end-user point of view, Skylight represents a radical improvement in health care delivery..
Rakovina Therapeutics Announces Preclinical Data Presentation...
Pre-clinical studies show potential synergy in treatment of solid tumors by combining a PARP inhibitor with inhibition of HDAC enzymes.
Skylight Health Announces Strategic Investment from U.S. Institutional Healthcare Firm
The funds will be used to support Skylight on its pathway to profitability.
Skylight Health to Participate in Medicaid Value-Based Care Model in Colorado
Skylight Health continues to see opportunities to expand value-based contracting efforts beyond traditional Medicare and Medicare Advantage.
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
The Company is finalizing the Phase 3 study protocol of apabetalone in PCC and plans to launch the trial in the first half of 2023..
Resverlogix will focus on the prevention and treatment of Post COVID-19 Conditions
The company’s new focus on patients with Post COVID-19 Conditions, known as long-COVID,
Skylight Health Expands Value-Based-Care Plan in Florida
Skylight Health continues to see opportunities to expand current and engage with new provider partners for MA value-based care...
Skylight Health Group NASDAQ:SLHG | TSXV:SLHG - a rapidly growing opportunity in value-based care
SLHG is focused on helping small and independent practices shift from a traditional fee-for-service model to value-based care...
Skylight Health Provides Clinical Research Update
Research revenue in 2022 has more than doubled the $300,000 earned in 2021. The team continues to plan for further expansion to new markets.
Resverlogix Publishes Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease..
“Apabetalone was associated not only with fewer negative cardiovascular outcomes, also relative improvements in liver fibrosis score"
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
The lead optimization program being conducted in collaboration with the University of British Columbia is progressing as planned...
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors.
Rakovina Presents Preclinical Data at the 2022 AACR Special Conference on Sarcomas
Rakovina highlighted the development of its kt-3000 drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tutors..
Resverlogix Announces Type C Meeting with FDA for Phase 3 High-risk COVID-19 Outpatient Study
FDA has granted the request for a meeting to review the clinical trial protocol for its Phase 3 study in high-risk COVID-19 outpatients.
Aduro Joins Canada Plastics Pact as a Signatory Partner
The CPP brings together businesses, policy makers, and NGOs to work together and create a national solution to plastic waste and pollution..
InvestmentPitch Media: Rakovina Therapeutics committed to advancing new cancer therapies
Rakovina Therapeutics - committed to advancing new cancer therapies presented at the American Association of Cancer Research Annual Meeting.
Rakovina Presents at the American Association of Cancer Research (AACR) Annual General Meeting..
The data presented suggested promising activity for bi-functional kt-4000 series compounds...
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas
Rakovina’s presentation will highlight the development of its drug candidates as a potential treatment of sarcomas and soft tissue tumors..
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal..
he article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p
Rakovina to Present at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)
Rakovina Therapeutics presentation will highlight pre-clinical research related to its novel kt-4000 series.
Rakovina Therapeutics Inc. TSXV: RKV
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies.
The Market Herald: Resverlogix (TSX:RVX) steps up Phase 2b study for COVID-19 treatment
Resverlogix has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for COVID-19 treatment..
Resverlogix Corp. TSX: RVX
Resverlogix’s clinical program is focused on evaluating apabetalone for the treatment of cardiovascular disease and COVID-19...
National Post: Rakovina preventing cancer cells from making DNA repairs they need to survive
The body’s cells have their DNA damaged daily. They correct this damage through a series of processes...
National Post: Calgary-based biotech firm specializes in instructing cells to fight complex diseases
Resverlogix researchers seek to find corrupted messages sent by DNA and correct the message that reaches our genes.
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 with 1st Site in Brazil and 2nd in Canada
A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon.
Resverlogix Commences Dosing of Patients in Phase 2b COVID-19 Trial
Enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton.
InvestmentPitch Media: Resverlogix Announces First Patient Dosing for Covid19 Clinical Trials
"Resverlogix has partnered with EVERSANA ™, a pioneer of next generation commercial services to the global life sciences industry, to...
CEO Clips: Resverlogix (TSX: RVX) | The Future of Drug Development
Resverlogix Corp. (TSX: RVX) is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic...
The Market Herald: Rakovina Therapeutics (TSXV:RKV) partners with St. Baldrick’s Foundation
"Rakovina (RKV) is partnering with St. Baldrick's Foundation to develop treatments for childhood bone cancer. It was selected to join a...
Rakovina Therapeutics Announces Non-dilutive Financial Contributions....
Funding will support the development of new research infrastructure for screening and optimization of potential drug candidates...
Resverlogix Announces Corporate Update Webcast and Conference Call
RVX will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST.
RKV Partners w. St. Baldrick’s Foundation to Research & Develop Treatments for Childhood Bone Cancer
Rakovina has been selected to join a three year US$975,000 (CDN1,297,000) research program funded by the St. Baldrick’s Foundation..
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy
This initiative will provide the necessary investments to advance apabetalone for potential treatment of Covid in the Arab-African Economy
Resverlogix in Active Discussions with The Kingdom of Morroco's Ministry of Health...
Apabetalone is the only drug of its class with a well-established safety record in human clinical trials...
Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference
Rakovina has been invited to present at the 6th biennial Canadian Cancer Research Conference which is being held virtually Nov. 8-11, 2021.
Rakovina Therapeutics Presents at the 2021 AACR- NCI-EORTC Virtual International Conference...
Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors..
Resverlogix : Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Apabetalone is the only drug of its class with a well-established safety record in human clinical trials, with well over 4200 patient-years
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series
The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics’ kt-2000 series...
Resverlogix: Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
"In February 2020, Apabetalone became the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a...
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot
Successful Completion and Promising Results of Investigator-led APPROACH-p Trial Sets the Stage for a Larger Multicenter Trial
The Good Shroom Co's Velada Cannabis Brand To be Listed for Sale in Ontario
Velada brand cannabis products both online and in store in the province of ON starting January 2022
Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference....
The conference has attracted academics, scientists, and pharmaceutical industry representatives from across the globe.....
The Good Shroom Co Signs Agreement with Rob Leichman of the Lyric Group to Lead its Retail Launch...
TGSC has also initiated a podcast marketing campaign with AdvertiseCast to continue expanding their e-commerce presence throughout NA..
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial..
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19...
InvestmentPitch Media:The Good Shroom Co contracts to sell its functional beverages through Ecotrend
Good Shroom, through its wholly owned subsidiary, Teonan, manufactures and sells functional beverages under its two brands, Teonan, a...
The Good Shroom Co Signs Contract With Top Tier Canadian Retail Distributor Ecotrend
MUSH is expected to gain exposure to Ecotrend Ecologics Ltd.'s network of 2,500 retailers in Canada, which includes Whole Foods, Well.ca...
Rakovina Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
Rakovina is pleased to report steady progress in research activities as they establish Rakovina as a publicly listed company...
Resverlogix Announces US$6 Million Debenture Financing
Agreement allows for Hepalink to purchase 10% secured convertible debentures in the aggregate principal amount of US$6 million...
bottom of page